BPC-157 and TB-500 research notes: origins, mechanisms and evidence

BPC-157 and TB-500 are two of the most discussed peptides in tissue repair research, and they are often spoken of as if they were one thing. These notes collect our short posts on where each came from, how each is thought to signal, and where the evidence runs thin.

Open question: which is more overstated relative to the data

We asked the research community which of the two peptides is discussed more loudly than its data supports, BPC-157 or TB-500, and to defend the answer.

The question is a fair one for both. Each has a body of animal work and a much louder online reputation, and the sections below look at what the research actually covers.

BPC-157, tendon models and the missing human trials

BPC-157 appears on the World Anti-Doping Agency prohibited list, a detail most tendon-repair discussion of the peptide leaves out.

The tendon research itself comes from rat models, which show faster fibroblast migration and better collagen organization at the injury site. No human trials exist behind those findings.

BPC-157 started as gastric research

BPC-157 was not developed with tendons in mind. It is a fragment of a protein found in human gastric juice, and it was first studied in stomach ulcer models.

The deepest body of BPC-157 research is still gastrointestinal: ulcer, inflammatory bowel disease and gut-damage models, built up over decades. The tendon literature came later and rests on thinner evidence.

Stability in gastric juice

Most peptides are broken down quickly by stomach acid. BPC-157 is an exception: it remains stable in gastric juice for more than 24 hours.

That stability is the reason BPC-157 research includes study designs in which the peptide has to pass through the digestive tract, something almost no other peptide in this space can survive.

TB-500 is a Thymosin Beta-4 fragment

TB-500 is neither a hormone nor a growth factor. It is a fragment of Thymosin Beta-4, the protein cells use to regulate actin, the structural filament that lets a cell change shape and move.

Animal studies show faster cell migration to injury sites. That is the mechanism under study: a signal tied to actin regulation and cell movement, not a broad repair effect.

Why the two should not be lumped together

BPC-157 and TB-500 are grouped together constantly, but they have different sequences, different mechanisms and entirely different research histories.

One is a fragment derived from a gastric protein with a deep gastrointestinal literature. The other is a fragment of Thymosin Beta-4 studied for its role in actin regulation. Discussing them as interchangeable hides both distinctions.

Open question: BPC-157 or GHK-Cu

We asked which of two peptides has the more interesting research behind it: BPC-157 or GHK-Cu.

The comparison is a useful one. BPC-157 rests mostly on animal models, while GHK-Cu is one of the few peptides in this niche with human trial data, covered in our skin and collagen notes.